Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.
5d
GlobalData on MSNSupernus wins FDA approval for Parkinson’s pump on fourth trySupernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...
4d
HealthDay on MSNFDA Approves Wearable Infusion Device for Advanced Parkinson DiseaseThe U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
1 “ONAPGO represents a novel approach for adults with Parkinson’s disease who are experiencing motor fluctuations,” said Jack Khattar, President and CEO of Supernus Pharmaceuticals.
The US Food and Drug Administration (FDA) has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection ...
Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...
The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...
Feb. 6. 2025 – The FDA has approved a new wearable device for adults with advanced Parkinson’s disease. Sold as Onapgo, this device gives a steady dose of apomorphine – a medicine that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results